Ionis Pharmaceuticals: A transformative surprise for the ATTR-CM space?

Research evidence excerpt

Ionis Pharmaceuticals: A transformative surprise for the ATTR-CM space?

sations are prohibited from re-publishing any opinion or recommendation

concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any recipients that do not want to continue

receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Unless clients have agreed to receive “institutional

debt research reports” as required by US FINRA Rule 2242, they will not receive any such reports that may be co-authored by non-debt research

analysts. Eligible clients may get access to such cross asset reports by contacting debtresearch@barclays.com. Barclays will not treat unauthorized

recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices

shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers,

directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue,

loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this

publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication (including third-party data) has been obtained from sources

that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete.